Announced details
Secondary screening of individuals who test positive for mucopolysaccharidosis (MPS) in newborn screening
For MPS I, sensitivity and specificity were both 100%; for MPS II, specificity was 100% under criteria requiring elevations in both dermatan sulfate and heparan sulfate.
ACRL is described as a clinical laboratory operated by AnGes,Inc.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Paper published in Biochemistry and Biophysics Reports
| Item | Details |
|---|---|
| Names of Products / Services Covered | Secondary screening test for mucopolysaccharidosis using dried blood spots |
| Relationship with the Company | ACRL is described as a clinical laboratory operated by AnGes,Inc. |
| Launch date | Since last year (as of 2 April 2026, the date of the announcement; actual results) |
| Applicable area | Secondary screening of individuals who test positive for mucopolysaccharidosis (MPS) in newborn screening |
| Quantitative Effects | For MPS I, sensitivity and specificity were both 100%; for MPS II, specificity was 100% under criteria requiring elevations in both dermatan sulfate and heparan sulfate. |
| Source | Paper published in Biochemistry and Biophysics Reports |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To reduce false positives caused by carrier status and pseudodeficiency, which are common among those who test positive in newborn screening, and to reduce the burden on families involved in urine collection and waiting for test results.